- News Home
10 April 2014 11:44 am ,
Vol. 344 ,
The Pyrenean ibex, an impressive mountain goat that lived in the central Pyrenees in Spain, went extinct in 2000. But a...
Tight budgets are forcing NASA to consider turning off one or more planetary science projects that have completed their...
Ebola is not a stranger to West Africa—an outbreak in the 1990s killed chimpanzees and sickened one researcher. But the...
In an as-yet-unpublished report, an international panel of geoscientists has concluded that a pair of deadly...
Tropical disease experts tried and failed before to eradicate yaws, a rare disfiguring disease of poor countries. Now,...
Since 2002, researchers have reported that agricultural communities in the hot and humid Pacific Coast of Central...
Balkan endemic kidney disease surfaced in the 1950s and for decades defied attempts to finger the cause. It occurred...
- 10 April 2014 11:44 am , Vol. 344 , #6180
- About Us
Morehouse Cardiologist Tapped to Head National Heart, Lung, and Blood Institute
5 April 2012 5:33 pm
Gary Gibbons, a cardiologist and scientist at Morehouse School of Medicine in Atlanta, today was named director of the National Heart, Lung, and Blood Institute (NHLBI).
At Morehouse, Gibbons, 55, founded and directs a cardiovascular research institute that focuses on areas including basic science and ethnic disparities in health. Gibbons's own lab studies how genetic variation influences vascular biology and cardiovascular disease. In an announcement, National Institutes of Health (NIH) Director Francis Collins praised Gibbons's "extraordinary scientific skills, tremendous energy and bold vision." He will join NIH this summer.
With a budget of $3.1 billion, NHLBI is the third-largest of NIH's 27 institutes and centers. The institute has not had a permanent director since Elizabeth Nabel left in late 2009 to head Brigham and Women's Hospital in Boston. Gibbons will bring to four the number of NIH institute directors (all men) who are African-American.
Gibbons told ScienceInsider he was interested in the job because of his "intimate" familiarity with NHLBI—he's a longtime grantee and adviser—and his commitment to "being sure that NHLBI continues its legacy of doing discovery science that advances public health." He would like to revisit the institute's strategic vision "with a renewed look that's more timely and contemporary."
Although NHLBI has been in good hands under acting director Susan Shurin (who will return to her post as deputy director), the lack of a permanent director has slowed decisions such as committing to large, costly clinical trials, says Leslee Shaw, a health outcomes researcher at Emory University and a member of the NHLBI advisory council. Gibbons's skill set is "kind of unique. He'll be able to slide up and down the interests of NHLBI and offer broad experience," Shaw says. She also praises his leadership style: "He's very thoughtful" and a "good listener."
One reason it may have taken so long to find a new NHLBI director is that clinicians often take a salary cut when they move to NIH. Candidates for top NIH jobs also might be put off by money problems: NIH's budget hasn't grown in a decade and could face cuts.